Stock Market News
Midatech Pharma reports boost for US operations
International pharmaceutical company Midatech Pharma guided towards an increase in full-year US product sales of at least 29% on Wednesday, as expected.
In a pre-close trading update, the Oxford based company announced sales from that country were expected to increase from £5.2m in 2016 to £6.7m, alongside an increase of at least 7% in total net revenues for the 12 months ending on 31 December from £6.9m to £7.4m.
Jim Phillips, chief executive of Midatech Pharma, said: "With our two lead candidates now approved to enter the clinic, and our established US commercial presence in the US delivering consistent growth, 2017 was a significant year in the Group's development and 2018 shows great promise."
The company's US operations reached break-even in H2 2017, subject to final audit approval, and were in the process of carrying out the first ever in-human clinical studies of Q-Octreotide for the treatment of carcinoid cancer and acromegaly.
They were expected to be completed in Q4 2018 or Q1 2019 and a study of MTX110 which is a treatment for the treatment of fatal childhood brain cancer was expected to conclude toward the end of 2019.
"Midatech is funded to support progression towards these and other value-driving product milestones and we eagerly await various value inflections points in 2018," said Phillips.
Midatech Pharma was supporting these trials with the aid of a $15m four-year senior loan facility which it secured from MidCap Financial in January, from which it initially drew down $7m.
As of 0909 GMT, Midatech Pharma's shares were unchanged at 36.50p.
In a pre-close trading update, the Oxford based company announced sales from that country were expected to increase from £5.2m in 2016 to £6.7m, alongside an increase of at least 7% in total net revenues for the 12 months ending on 31 December from £6.9m to £7.4m.
Jim Phillips, chief executive of Midatech Pharma, said: "With our two lead candidates now approved to enter the clinic, and our established US commercial presence in the US delivering consistent growth, 2017 was a significant year in the Group's development and 2018 shows great promise."
The company's US operations reached break-even in H2 2017, subject to final audit approval, and were in the process of carrying out the first ever in-human clinical studies of Q-Octreotide for the treatment of carcinoid cancer and acromegaly.
They were expected to be completed in Q4 2018 or Q1 2019 and a study of MTX110 which is a treatment for the treatment of fatal childhood brain cancer was expected to conclude toward the end of 2019.
"Midatech is funded to support progression towards these and other value-driving product milestones and we eagerly await various value inflections points in 2018," said Phillips.
Midatech Pharma was supporting these trials with the aid of a $15m four-year senior loan facility which it secured from MidCap Financial in January, from which it initially drew down $7m.
As of 0909 GMT, Midatech Pharma's shares were unchanged at 36.50p.
Related share prices |
---|
Midatech Pharma (MTPH) share price |
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price